Ji Hyun Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ji Hyun Lee has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Suee Lee
Division of Hematology and Oncology Department of Internal Medicine Dong-A University College of Medicine Busan Korea
2 shared publications - Sung Yong Oh
Department of Internal Medicine Dong‐A University College of Medicine Busan Republic of Korea
2 shared publications - Sung-Hyun Kim
12Division of Hematology-Oncology, Department of Internal Medicine, Dong-A University College of Medicine, Busan, Republic of Korea
2 shared publications - Christian A Graves
Radiation Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA
1 shared publication - Hyo- Jeon Kim
Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea
1 shared publication - Hyojin Kim
Department of Pathology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
1 shared publication
Latest Publications
- Open Access
- 22 July 2013
- Published by Springer Nature in BMC Cancer
- Vol. 13 (1) , 350
Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy
Background: Several inflammatory response materials could be used for prediction of prognosis of cancer patients. The neutrophil lymphocyte ratio (NLR), and the platelet lymphocyte ratio (PLR) have been introduced for prognostic scoring system in various cancers. The objective of this study was to determine whether the NLR or the PLR would predict the clinical outcomes in advanced gastric cancer patients treated with oxaliplatin/ 5-fluorouracil (FOLFOX).Methods: The study population consisted of 174 advanced gastric cancer patients. Patients were treated with 85 mg/m2of oxaliplatin as a 2-h infusion at day 1 plus 20 mg/m2of leucovorin over 10 min, followed by 5-FU bolus 400 mg/m2and 22-h continuous infusion of 600 mg/m2at days 1-2. Treatment was repeated in 2-week intervals. The NLR and PLR were calculated from complete blood counts in laboratory test before and after first cycle of chemotherapy.Results: NLR was a useful prognostic biomarker for predicting inferior overall survival (OS) (p= 0.005), but was not associated with progression free survival (PFS) (p= 0.461). The normalization of NLR after one cycle of chemotherapy was found to be in association with significant improvement in PFS (5.3 months vs. 2.4 months,p< 0.001), and OS (11.9 months vs. 4.6 months,p< 0.001). The normalization of PLR was also associated with longer PFS (5.6 months vs. 3.4 months,p= 0.006), and OS (16.9 months vs. 10.9 months,p= 0.002). In multivariate analysis, changes in NLR were associated with PFS (Hazard ratio (HR): 2.297, 95% confidence interval (CI): 1.429-3.693,p= 0.001). The NLR, (HR: 0.245, 95% CI: 0.092-0.633,p= 0.004), PLR (HR: 0.347, 95% CI: 0.142-0.847,p= 0.020), changes in NLR (HR: 2.468, 95% CI: 1.567-3.886,p< 0.001), and changes in PLR (HR: 1.473, 95% CI: 1.038-2.090,p= 0.030) were independent prognostic markers for OS.Conclusion: This study demonstrates that NLR, PLR, and changes in NLR or PLR are independent prognostic factor for OS in patients with advanced gastric cancer treated with chemotherapy. These specific factors may also help in identifying the patients, who are more sensitive to FOLFOX regimen.
- 22 July 2013
- Published by Springer Nature in BMC Cancer
- Vol. 13 (1) , 350
Open AccessPrognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy
Background: Several inflammatory response materials could be used for prediction of prognosis of cancer patients. The neutrophil lymphocyte ratio (NLR), and the platelet lymphocyte ratio (PLR) have been introduced for prognostic scoring system in various cancers. The objective of this study was to determine whether the NLR or the PLR would predict the clinical outcomes in advanced gastric cancer patients treated with oxaliplatin/ 5-fluorouracil (FOLFOX).Methods: The study population consisted of 174 advanced gastric cancer patients. Patients were treated with 85 mg/m2of oxaliplatin as a 2-h infusion at day 1 plus 20 mg/m2of leucovorin over 10 min, followed by 5-FU bolus 400 mg/m2and 22-h continuous infusion of 600 mg/m2at days 1-2. Treatment was repeated in 2-week intervals. The NLR and PLR were calculated from complete blood counts in laboratory test before and after first cycle of chemotherapy.Results: NLR was a useful prognostic biomarker for predicting inferior overall survival (OS) (p= 0.005), but was not associated with progression free survival (PFS) (p= 0.461). The normalization of NLR after one cycle of chemotherapy was found to be in association with significant improvement in PFS (5.3 months vs. 2.4 months,p< 0.001), and OS (11.9 months vs. 4.6 months,p< 0.001). The normalization of PLR was also associated with longer PFS (5.6 months vs. 3.4 months,p= 0.006), and OS (16.9 months vs. 10.9 months,p= 0.002). In multivariate analysis, changes in NLR were associated with PFS (Hazard ratio (HR): 2.297, 95% confidence interval (CI): 1.429-3.693,p= 0.001). The NLR, (HR: 0.245, 95% CI: 0.092-0.633,p= 0.004), PLR (HR: 0.347, 95% CI: 0.142-0.847,p= 0.020), changes in NLR (HR: 2.468, 95% CI: 1.567-3.886,p< 0.001), and changes in PLR (HR: 1.473, 95% CI: 1.038-2.090,p= 0.030) were independent prognostic markers for OS.Conclusion: This study demonstrates that NLR, PLR, and changes in NLR or PLR are independent prognostic factor for OS in patients with advanced gastric cancer treated with chemotherapy. These specific factors may also help in identifying the patients, who are more sensitive to FOLFOX regimen.
- Open Access
- 1 February 2013
- Published by Springer Nature in BMC Cancer
- Vol. 13 (1) , 43
The relationship of Vascular endothelial growth factor gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX: VEGF polymorphism in gastric cancer
The aim of this study is to evaluate the associations between vascular endothelial growth factor (VEGF) Single-nucleotide polymorphisms (SNPs) and clinical outcome in advanced gastric cancer patients treated with oxaliplatin, 5-fluorouracil, and leucovorin (FOLFOX).
- 1 February 2013
- Published by Springer Nature in BMC Cancer
- Vol. 13 (1) , 43
Open AccessThe relationship of Vascular endothelial growth factor gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX: VEGF polymorphism in gastric cancer
The aim of this study is to evaluate the associations between vascular endothelial growth factor (VEGF) Single-nucleotide polymorphisms (SNPs) and clinical outcome in advanced gastric cancer patients treated with oxaliplatin, 5-fluorouracil, and leucovorin (FOLFOX).